Eli Lilly and Company has an OGA inhibitor (LY3372689) advancing to stage 2 clinical trial targeting tau O-GlcNAcylation for early symptomatic AD (ClinicalTrials.gov Identifier: NCT05063539). This evidence concerns the gene MAPT and Alzheimer disease.